ReviewJournal of invertebrate pathology2011
Large-scale production and purification of VLP-based vaccines.
Review in Journal of invertebrate pathology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
101 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Downstream Purification Strategies for Virus-like Particles: A Systematic Review of Structure Preservation, Impurity Control, and Viral Safety.Microorganisms · 2026Review
- Development of a scalable production bioprocess for HIV-1 virus-like particles coupling continuous VLP harvesting with end-to-end downstream processing.Scientific reports · 2026Article
- Influenza Neuraminidase Virus-Like Particle-Based Nanocarriers as a New Platform for the Delivery of Small-Peptide Antigens.Molecular biotechnology · 2026Article
- Enhancing CRISPR Homology Directed Repair in IAL-PiD2 Insect Cells via Reagent Delivery Optimization and Cell Synchronization.Biochemical engineering journal · 2026Article
- Harnessing Nanocarriers to Advance Vaccine Development.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Innovations in HPV vaccination and their role in global cervical cancer control: a review.Therapeutic advances in vaccines and immunotherapy · 2026Review
- Zika virus-like particle production in a stirred tank bioreactor using a baculovirus/insect cell system.Bioprocess and biosystems engineering · 2025Article
- Production Optimization, Adjuvant Screening and Immunogenicity Evaluation of a Virus-like Vesicle Rabies Vaccine.Vaccines · 2025Article
- Modular Virus-like Particles for Antigen Presentation: Comparing Genetic Fusion and Click-Chemistry for Purification.International journal of molecular sciences · 2025Article
- Virus-like Particles Formed by the Coat Protein of the Single-Stranded RNA Phage PQ465 as a Carrier for Antigen Presentation.Molecules (Basel, Switzerland) · 2025Article
- Review
- Development of Methods to Produce SARS CoV-2 Virus-Like Particles at Scale.Biotechnology and bioengineering · 2025Article
- Recent Advances in Antiviral Drug Delivery Strategies.AAPS PharmSciTech · 2025Review
- Overcoming dengue vaccine challenges through next-generation virus-like particle immunization strategies.Frontiers in cellular and infection microbiology · 2025Review
- Review
- Viral and nonviral nanocarriers forNano research · 2024Article
- Virus-like Particles as Vaccines for Allergen-Specific Therapy: An Overview of Current Developments.International journal of molecular sciences · 2024Review
- Article
- Production of norovirus-, rotavirus-, and enterovirus-like particles in insect cells is simplified by plasmid-based expression.Scientific reports · 2024Article
41 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Virus-like particles (VLPs) hold tremendous potential as vaccine candidates. These innovative biopharmaceuticals present the remarkable advantages of closely mimicking the three-dimensional nature of an actual virus while lacking the virus genome packaged inside its capsid. As a result, an equally efficient but safer prophylaxis is anticipated as compared to inactivated or live attenuated viral vaccines. With the advent of successful cases of approved VLP-based vaccines, pharmaceutical companies are indeed redirecting their resources to the development of such products. This paper reviews the current choices and trends of large-scale production and purification of VLP-based vaccines generated through the baculovirus expression vector system using insect cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.